First Cited
Last Cited

Articles citing This Document (Page 1 of 16)

The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non–small cell lung cancer: A multicenter retrospective cohort study2022
Safety and efficacy of pralsetinib in RET fusion–positive non-small cell lung cancer including as first-line therapy: update from the ARROW trial2022
Role of Stereotactic Radiation Therapy in Operable and Inoperable Early-Stage Non-small Cell Lung Cancer2022
Evaluation of the synergistic impact of needle and forceps biopsy with electromagnetic navigation bronchoscopy: the CONFIDENT-ENB trial design2022
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial2022
Characterizing the Shifting Real-World Treatment Landscape by PD-L1 Testing Status and Expression Level in Advanced Non-Small Cell Lung Cancer
EGFR-mutant NSCLC: monitoring the molecular evolution of tumors in 2022
Survival benefits of primary tumor surgery for synchronous brain metastases: A SEER ‐based population study with propensity‐matched comparative analysis
Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report2022
Older Patients with Lung Cancer: a Summary of Seminal Contributions to Optimal Patient Care
Multi-Gene Mutation Profiling by Targeted Next-Generation Sequencing in Premenopausal Breast Cancer2022
Role of Radiologic Imaging in Lung Cancer2022
Malignancies in HIV2021
Expert opinion on NSCLC small specimen biomarker testing — Part 1: Tissue collection and managementVirchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin
The Association between Muscle Quantity and Overall Survival Depends on Muscle Radiodensity: A Cohort Study in Non-Small-Cell Lung Cancer PatientsJournal of Personalized Medicine2022
Practical considerations of single-fraction stereotactic ablative radiotherapy to the lungLung Cancer2022
Long-term survival of patients with central or > 7 cm T4 N0/1 M0 non-small-cell lung cancer treated with definitive concurrent radiochemotherapy in comparison to trimodality treatmentRadiation Oncology2022
Molecular biomarkers and liquid biopsies in lung cancerSeminars in Oncology2022
A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC)Expert Opinion on Pharmacotherapy
Disparate Access to Surgery for Operable Carcinoma of the Lung in North CarolinaAnnals of Surgical Oncology
Prognostic significance of location index in resected T1-sized early-stage non-small cell lung cancerActa Radiologica
Postoperative tegafur–uracil for stage I lung adenocarcinoma: first real-world data with an exploratory subgroup analysisSurgery Today
Variants of ERCC5 and the outcome of platinum-based regimens in non-small cell lung cancer: a prospective cohort study2022
Pulmonary Segmentectomy: A New Standard of Care in Patients with Non-Small Cell CancerJournal of Cardiothoracic and Vascular Anesthesia2022
Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung CancerCurrent Oncology2022
Real-World Clinical Outcomes after Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Advanced Non-Small Cell Lung CancerCurrent Oncology2022
Rationale for Combing Stereotactic Body Radiation Therapy with Immune Checkpoint Inhibitors in Medically Inoperable Early-Stage Non-Small Cell Lung CancerCancers2022
The Impact of Enhanced Recovery After Surgery on Persistent Opioid Use Following Pulmonary ResectionAnnals of Thoracic Surgery2022
Low-dose computed tomography screening, follow-up, and management of lung nodules – An expert consensus statement from TaiwanFormosan Journal of Surgery2022
Circulating cancer biomarkers: current status and future prospects2022
Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United StatesJournal of Medical Economics2022
Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung CancerCurrent Treatment Options in Oncology
Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLCClinical Medicine Insights: Oncology2022
Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50%Therapeutic Advances in Medical Oncology2022
Three-port single-intercostal versus uniportal thoracoscopic segmentectomy for the treatment of lung cancer: a propensity score matching analysisWorld Journal of Surgical Oncology2022
Targeting EGFR Exon 20 Insertion Mutation in Non–small cell Lung Cancer: Amivantamab and MobocertinibAnnals of Pharmacotherapy
Lack of an association between marital status and survival in patients receiving stereotactic body radiotherapy for early-stage non-small-cell lung cancerPLoS ONE2022
Development and validation of a computed tomography–based immune ecosystem diversity index as an imaging biomarker in non-small cell lung cancerEuropean Radiology
Salvage surgery for local recurrence after sublobar surgery in Stages I and II non‐small cell lung cancerJournal of Surgical Oncology
Association of Diabetes Severity and Mortality with Lung Squamous Cell CarcinomaCancers2022
FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer PatientsSeminars in Nuclear Medicine2022
Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNACancers2022
All EGFR mutations are (not) created equal: focus on uncommon EGFR mutations.Journal of Cancer Research and Clinical Oncology2022
Allele frequency and proportion defined by circulating tumor DNA profiling predict tyrosine kinase inhibitors' therapeutic outcomes for non-small cell lung cancer.Journal of Cancer Research and Clinical Oncology2022
Development and validation of ACTE-MTB: A tool to systematically assess the maturity of molecular tumor boards.PLoS ONE2022
Use of the Biocartis Idylla™ Platform for the Detection of Epidermal Growth Factor Receptor, BRAF and KRAS Proto-Oncogene Mutations in Liquid-Based Cytology Specimens from Patients with Non-Small Cell Lung Carcinoma and Pancreatic AdenocarcinomaJournal of Molecular Pathology2022
Oncological Diseases2022
BRAF in lung cancer: A narrative reviewCancer Research Statistics and Treatment2021
Patient perception of burden of disease and treatment preferences in non-small cell lung cancer: Results from a European survey.Lung Cancer2022